ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
Cherrie K. Donawho(Abbott Fund), David J. Frost(Abbott Fund), Luis E. Rodrı́guez(Abbott Fund), Joann P. Palma(Abbott Fund), Thomas D. Penning(Abbott Fund), Kenneth B. Idler(Abbott Fund), Vered Klinghofer(Abbott Fund), Larry E. Dillehay(Johns Hopkins University), Rhonda R. Holley-Shanks(Abbott Fund), Kennan C. Marsh(AbbVie (United States)), Vincent L. Giranda(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lawrence Kleinberg(Johns Hopkins University), Yan Shi(Abbott Fund), Jennifer J. Bouska(Abbott Fund), Jason Stavropoulos(Abbott Fund), Velitchka Bontcheva-Diaz(Abbott Fund), Loren Lasko(AbbVie (United States)), Debra C. Ferguson(AbbVie (United States)), Jonathan A. Meulbroek(Abbott Fund), Nayereh Ghoreishi‐Haack(Abbott Fund), Ran Guan(Abbott Fund), Alan C. Tsurutani(Abbott Fund), David R. Grimm(Stanford Medicine), Eric F. Johnson(Pfizer (United States)), Amanda M. Olson(Abbott Fund), Xuesong Liu(Tianjin Institute of Pharmaceutical Research (China)), Yan Luo(AbbVie (United States)), Ken Jarvis(Abbott Fund), Gui‐Dong Zhu(Abbott Fund), Boris Hristov(Johns Hopkins University), Bryan F. Cox(Abbott Fund), Thomas McGonigal(Abbott Fund), Joy Bauch(Abbott Fund), Saul H. Rosenberg(Abbott Fund), Edward K. Han(Abbott Fund), Yanping Luo(Abbott Fund), Theodore L. DeWeese(Johns Hopkins University)
Cited by 770
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
ABC transporters: the power to change
|Nature Reviews Molecular Cell Biology|2009|1.4k